Preclinical News and Research

RSS

Scientists successfully test new tumor diagnosis method

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf, in cooperation with colleagues at the University of Zurich and the Ruhr-Universität Bochum, have for the first time successfully tested a new tumor diagnosis method under near-real conditions. The new method first sends out an antibody as a "spy" to detect the diseased cells and then binds to them.

4 Aug 2015

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery.

4 Aug 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015

Research shows specific routes of administration can predict risk of drug addiction

Abstinence is the best way to avoid drug addiction. But in many societies, drug use is the norm, not the exception, especially by youth.

3 Aug 2015

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.

31 Jul 2015

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.

31 Jul 2015

Vismodegib therapy effective against medulloblastoma

A targeted therapy already used to treat advanced skin cancer is also effective against the most common subtype of the brain tumor medulloblastoma in adults and should be considered for treatment of newly diagnosed patients, according to research led by St. Jude Children's Research Hospital.

30 Jul 2015

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted in the United Kingdom, is a double-blind, two-way cross-over design lipopolysaccharide (LPS) challenge study further evaluating the safety and tolerability of MMI-0100 when given via inhalation to healthy subjects who smoke.

29 Jul 2015

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology.

29 Jul 2015

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

28 Jul 2015

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma's Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively.

23 Jul 2015

Important new target identified for ovarian cancer therapy

Scientists at Lawson Health Research Institute have uncovered an important new target for ovarian cancer therapy. Contrary to current research this new study found that LKB1, a molecule that regulates the metabolism of many adult cells, is an important molecule in the cancer's promotion and survival.

23 Jul 2015

Gene responsible for cancer growth plays unexpected role in prostate cancer

A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.

22 Jul 2015

Dairy products could make probiotics more effective

The success of probiotics for boosting human health may depend partly upon the food, beverage, or other material carrying the probiotics, according to research published on July 10th in Applied and Environmental Microbiology, a journal of the American Society for Microbiology.

22 Jul 2015

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

22 Jul 2015

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem of antibiotic resistance today announces that the first group of healthy male volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3, for use in the treatment of Clostridium difficile infections.

21 Jul 2015

Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

Approximately 30,000-40,000 people die from liver disease each year, according to the American Liver Foundation. For people who experience acute liver failure, the only proven treatment has been liver transplantation. Researchers at Mayo Clinic have developed and are testing an alternative to liver transplantation called the Spheroid Reservoir Bioartificial Liver that can support healing and regeneration of the injured liver, and improve outcomes and reduce mortality rates for patients with acute liver failure — without requiring a transplant.

20 Jul 2015

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C2N Diagnostics and AbbVie today announced that the U.S. Food and Drug Administration has granted their investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), an orphan drug designation for the treatment of progressive supranuclear palsy (PSP).

17 Jul 2015

Adverse life events in childhood can increase woman's risk of preterm birth

Like most health professionals, David Olson has known for some time of the dangers posed by excessive stress. His latest research, though, is giving surprising new insight into how chronic stress in childhood can have an impact years after it occurred in women giving birth.

17 Jul 2015

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.

16 Jul 2015

Preclinical News and Research

Scientists successfully test new tumor diagnosis method

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

Shire acquires Foresight Biotherapeutics for $300 million

Research shows specific routes of administration can predict risk of drug addiction

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Vismodegib therapy effective against medulloblastoma

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Researchers establish safety, dosing of new drug for treating blood cancers

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

SutroVax completes $22 million Series A financing

Important new target identified for ovarian cancer therapy

Gene responsible for cancer growth plays unexpected role in prostate cancer

Dairy products could make probiotics more effective

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

MGB Biopharma begins MGB-BP-3 Phase I clinical trial for treatment of Clostridium difficile infections

Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

Adverse life events in childhood can increase woman's risk of preterm birth

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics